306 related articles for article (PubMed ID: 33585182)
1. Novel Combination Therapies for the Treatment of Bladder Cancer.
Peng M; Xiao D; Bu Y; Long J; Yang X; Lv S; Yang X
Front Oncol; 2020; 10():539527. PubMed ID: 33585182
[TBL] [Abstract][Full Text] [Related]
2. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.
Xiao JF; Caliri AW; Duex JE; Theodorescu D
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638374
[TBL] [Abstract][Full Text] [Related]
3. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
4. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
Casadei C; Dizman N; Schepisi G; Cursano MC; Basso U; Santini D; Pal SK; De Giorgi U
Ther Adv Med Oncol; 2019; 11():1758835919890285. PubMed ID: 31803255
[TBL] [Abstract][Full Text] [Related]
5. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
6. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
7. Erdafitinib for the treatment of urothelial cancer.
Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
[No Abstract] [Full Text] [Related]
8. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
Grivas P; Yu EY
Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
Peng M; Chu X; Peng Y; Li D; Zhang Z; Wang W; Zhou X; Xiao D; Yang X
MedComm (2020); 2023 Dec; 4(6):e455. PubMed ID: 38107059
[TBL] [Abstract][Full Text] [Related]
10. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
11. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors.
Luo H; Zhang T; Cheng P; Li D; Ogorodniitchouk O; Lahmamssi C; Wang G; Lan M
Oncol Lett; 2020 Sep; 20(3):2525-2536. PubMed ID: 32782571
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy: new applications in urologic oncology.
Hurwitz ME; Sokhn J; Petrylak DP
Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
[TBL] [Abstract][Full Text] [Related]
14. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Jia Y; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor in bladder cancer: A promising therapeutic target.
Tripathi A; Gupta S
Asian J Urol; 2020 Jul; 7(3):284-290. PubMed ID: 32742928
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies.
Maung TZ; Ergin HE; Javed M; Inga EE; Khan S
Cureus; 2020 May; 12(5):e8095. PubMed ID: 32542150
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
Bergerot P; Lamb P; Wang E; Pal SK
Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
